Vir Biotechnology Stock: Fairly Valued After Phase 3 Success? (NASDAQ:VIR)
· seekingalpha.com
Vir Biotechnology remains a Buy after flawless Phase 3 ECLIPSE 1 results and a major new Gilead partnership. Read more on VIR stock here.
About six months ago, I wrote an article on Vir Biotechnology, Inc. ( VIR ) following their massive $1.7 billion collaboration agreement with Astellas Pharma. M...